- Home
- JHI vs BDTX Comparison
JHI vs BDTX Comparison
Compare JHI & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JHI | BDTX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.3M | 116.8M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JHI | BDTX |
|---|---|---|
| Price | $12.60 | $2.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.20 |
| AVG Volume (30 Days) | 23.1K | ★ 571.5K |
| Earning Date | 01-01-0001 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.46 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.61 | $1.20 |
| 52 Week High | $14.51 | $4.94 |
Technical Indicators
Market Signals| Indicator | JHI | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 25.50 | 39.11 |
| Support Level | N/A | $1.93 |
| Resistance Level | $14.01 | $2.30 |
| Average True Range (ATR) | 0.18 | 0.11 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 1.00 | 1.82 |
Price Performance
Historical ComparisonAbout JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others. The company's portfolio includes Corporate Bonds, Term Loans, U.S Government Agency, and Others.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.